Quarterly report pursuant to Section 13 or 15(d)

Inventories, net - Shelf-life (Details)

v3.22.2.2
Inventories, net - Shelf-life (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Aug. 31, 2022
USD ($)
Aug. 31, 2021
USD ($)
[1]
May 31, 2022
USD ($)
item
Inventory Realizable Value      
2023 $ 6,903    
2024 20,201    
2025 31,241    
2026 35,779    
Inventories, gross 94,124    
Inventory charge (76,195)    
Inventories, net 17,929   $ 17,929
Raw materials, net of reserves     10,200
Raw materials 16,264   $ 16,264
Inventory write-off 2,704 $ 1,764  
Number of batches not saleable | item     5
Total number of batches manufactured | item     9
Other Assets | Samsung BioLogics Co., Ltd. ("Samsung")      
Inventory Realizable Value      
Specialized raw materials 2,700    
Raw Materials      
Inventory Realizable Value      
2023 5,079    
2024 18,536    
2025 2,099    
2026 3,435    
Inventories, gross 29,149    
Inventory charge (12,885)    
Inventories, net 16,264    
Specialized      
Inventory Realizable Value      
2023 3,658    
2024 682    
2025 2,099    
2026 3,435    
Inventories, gross 9,874    
Inventory charge (9,874)    
Resins      
Inventory Realizable Value      
2024 16,264    
Inventories, gross 16,264    
Inventories, net 16,264    
Resins | Minimum      
Inventory Realizable Value      
Remaining cycles of resins     37
Resins | Maximum      
Inventory Realizable Value      
Remaining cycles of resins     62
Other      
Inventory Realizable Value      
2023 1,421    
2024 1,590    
Inventories, gross 3,011    
Inventory charge (3,011)    
Inventory write-off     $ 63,300
Number of batches not saleable | item     4
Five Batches Of Drug Product      
Inventory Realizable Value      
Raw materials     $ 29,100
Four Batches Of Drug Product      
Inventory Realizable Value      
Raw materials     $ 34,200
Bulk Drug Substance      
Inventory Realizable Value      
2023 1,824    
2024 1,665    
Inventories, gross 3,489    
Inventory charge (1,824)    
Inventories, net $ 1,665    
Shelf life 4 years   4 years
Drug Products      
Inventory Realizable Value      
2025 $ 29,142    
2026 32,344    
Inventories, gross 61,486    
Inventory charge $ (61,486)    
[1] See Note 2, Summary of Significant Accounting Policies.